FLEQSUVY Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Fleqsuvy, and what generic alternatives are available?
Fleqsuvy is a drug marketed by Azurity and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has four patent family members in four countries.
The generic ingredient in FLEQSUVY is baclofen. There are twenty-one drug master file entries for this compound. Sixty-five suppliers are listed for this compound. Additional details are available on the baclofen profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Fleqsuvy
A generic version of FLEQSUVY was approved as baclofen by IVAX SUB TEVA PHARMS on July 21st, 1988.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for FLEQSUVY?
- What are the global sales for FLEQSUVY?
- What is Average Wholesale Price for FLEQSUVY?
Summary for FLEQSUVY
International Patents: | 4 |
US Patents: | 2 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 3 |
Raw Ingredient (Bulk) Api Vendors: | 150 |
Patent Applications: | 3,917 |
Drug Prices: | Drug price information for FLEQSUVY |
What excipients (inactive ingredients) are in FLEQSUVY? | FLEQSUVY excipients list |
DailyMed Link: | FLEQSUVY at DailyMed |
Pharmacology for FLEQSUVY
Drug Class | gamma-Aminobutyric Acid-ergic Agonist |
Mechanism of Action | GABA A Agonists GABA B Agonists |
US Patents and Regulatory Information for FLEQSUVY
FLEQSUVY is protected by two US patents.
Patents protecting FLEQSUVY
Suspensions and diluents for metronidazole and baclofen
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: INDICATED FOR THE TREATMENT OF SPASTICITY RESULTING FROM MULTIPLE SCLEROSIS
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Azurity | FLEQSUVY | baclofen | SUSPENSION;ORAL | 215602-001 | Feb 4, 2022 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Azurity | FLEQSUVY | baclofen | SUSPENSION;ORAL | 215602-001 | Feb 4, 2022 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for FLEQSUVY
See the table below for patents covering FLEQSUVY around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
China | 109922801 | 甲硝唑和巴氯芬的混悬剂和稀释剂 (SUSPENSIONS AND DILUENTS FOR METRONIDAZOLE AND BACLOFEN) | ⤷ Sign Up |
World Intellectual Property Organization (WIPO) | 2018049184 | ⤷ Sign Up | |
Canada | 3036356 | SUSPENSIONS ET DILUANTS POUR LE METRONIDAZOLE ET LE BACLOFENE (SUSPENSIONS AND DILUENTS FOR METRONIDAZOLE AND BACLOFEN) | ⤷ Sign Up |
European Patent Office | 3509592 | SUSPENSIONS ET DILUANTS POUR LE MÉTRONIDAZOLE ET LE BACLOFÈNE (SUSPENSIONS AND DILUENTS FOR METRONIDAZOLE AND BACLOFEN) | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |